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A b s t r a c t
Introduction: Despite the continuous improvement of the quality of lipid low-
ering therapy the achievement of target values is still not satisfactory, mainly
in the very high cardiovascular risk category patients, where the goal of low
density lipoprotein cholesterol (LDL-C) is 1.80 mmol/l. 
Material and methods: The trends in lipid lowering treatment of 17420 patients
from different studies conducted between 2004 and 2010 were compared to
that of 1626 patients of MULTI GAP (MULTI Goal Attainment Problem) 2011 treat-
ed by general practitioners (GPs) and specialists.
Results: In MULTI GAP 2011 the mean LDL-C level ± SD) of patients treated by
GPs was found to be 2.87 ±1.01 mmol/l, the target value of 2.50 was achieved
by 40% of them, in the specialists’ patients the mean LDL-C level proved to be
2.77 ±1.10 mmol/l and the achievement rate was 45%. In the 2.50 mmol/l
achievement rate of GPs’ patients a satisfactory improvement was observed in
the studied years, but the 1.80 mmol/l LDL-C goal in 2011 was attained only in
11% of very high risk cases. There was a linear correlation between the patient
compliance estimated by the physicians and the LDL-C achievement rate.
Conclusions: As the number of very high risk category patients has been
increased according to the new European dyslipidemia guidelines, growing atten-
tion needs to be placed on attainment of the 1.80 mmol/l LDL-C level. Based on
the results of the MULTI GAP studies, improving patients’ adherence and the
continuous training of physicians are necessary. 
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Introduction
Lipid-lowering therapy, the basic drugs of which are statins, became
cardiovascular prevention’s most important element in recent years.
A series of studies showed that the administration of statins can reduce
cardiovascular events and mortality as well [1-3]. Recently the issue came
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up that this group of medicines could increase the
occurrence of new onset diabetes; however, the
benefit of statin application is not comparable to
the harm of this possible side effect, especially in
patients with known vascular disease [4-6].
The goal of lipid-lowering therapy is always to
reduce the frequency of cardiovascular events. How-
ever, within this there is a well-defined surrogate
endpoint of stopping the progression or causing the
regression of atherosclerosis that is considered the
cause the clinical events. A series of studies has
proved that lowering the LDL-C level by 50% could
result in regression of atherosclerotic plaques [7-9].
All this makes understandable the fact that in the
new European dyslipidemia guidelines the number
of diseases belonging to the very high risk catego-
ry has been enlarged [10]. If vascular stenosis is
detected, an effort should be made to stop the
process and start its regression, aiming to reach the
1.80 mmol/l target level and exceed the 50% reduc-
tion of LDL-cholesterol level.
Most of the previous studies demonstrated that
the attainment rate of the 2.50 mmol/l LDL-C level
is insufficient. How can we reach this target when
most of our patients should achieve the 1.80 mmol/l
LDL-C level already? What conclusions can be drawn
from the survey conducted since 2004 and the
MULTI GAP 2011 results in order to treat our
patients more effectively? Although this survey was
conducted in Hungary, the comparison made with
the earlier international studies showed that the
problems are similar in all European countries 
[11-16]; therefore we believe that the lessons
learned from this investigation may be valid for oth-
er countries as well.
Material and methods
The trends in lipid lowering treatment were stud-
ied using the data of 17 420 patients in total from
different surveys (CEL Program 2004 and 2005,
KONSZENZUS-CEL Program 2006, REALITY 2004 and
2007 studies, MULTI GAP 2008, 2009 and 2010) per-
formed on high cardiovascular risk patients of GPs
and specialists in Hungary [17, 18]. 
In the MULTI-GAP 2011 study we analyzed data
and treatment strategies of 1626 patients from 149
randomly selected specialists (73 specialists of
internal medicine, 40 cardiologists, 16 diabetolo-
gists, 20 neurologists) and 53 GPs (approximately
10 patients per physician were enrolled) using
a structured questionnaire in August and Septem-
ber 2011. 
The patients gave their consent to participation;
the study was conducted in accordance with the Dec-
laration of Helsinki and ICH-GCP (International Con-
ference on Harmonisation – Good Clinical Practice). 
The MULTI GAP 2011 patients involved 383 cas-
es of unstable angina, 560 cases of previous
myocardial infarction, 283 with known peripheral
artery disease (PAD) or vascular operation due to
PAD, 481 with stroke and 279 with transitory
ischemic attack; 766 patients were diabetic and
1430 had hypertension. The existence and extent
of smoking, as well as the sex, age, body mass
index and waist circumference were recorded. 
The physicians also estimated patients’ compli-
ance based on frequency of statin prescription and
questioning the patient.
All patients belonged at least to the high car-
diovascular risk category according to the 4th Hun-
garian Cardiovascular Consensus Conference rec-
ommendations [19], and they had LDL-C targets at
least of ≤ 2.50 mmol/l. Stratifying the patients
according the new dyslipidemia guidelines of the
ESC/EAS (European Society of Cardiology and Euro-
pean Atherosclerosis Society), 83% of them
belonged to the very high risk category with an LDL-C
target value of 1.80 mmol/l [10]. 
Statistical analysis 
In the case of categorical variables we used fre-
quencies of valid cases. In the case of continuous
variables means and medians are presented. Sig-
nificance tests were performed by χ2 for categori-
cal, by ANOVA for continuous variables (with Fish-
er’s least significant difference [LSD] test method
for multiple comparisons). Asymmetric 2-sided
scores were considered. Values of p (two-tailed)
< 0.05 were accepted as significant. All statistical
analyses were performed by SPSS.
Results
In the MULTI GAP 2011 study 1626 patients par-
ticipated, 683 women and 943 men; their mean age
was 66.0 ±10 years, body mass index 29.0 ±10 kg/m2,
eGFR 61 ±13 ml/min/1.73 m2, 28% of the patients
were smokers (among the smokers 28% smoked 
10 or less cigarettes/day, 48% between 10 and 20,
and 24% 20 or more) (Table I). 
The mean LDL-C level (± SD) of the total popu-
lation was 2.82 ±1.0 mmol/l, the attainment rate 
of 2.50 mmol/l was 43.3%. The mean LDL-C val-
ues of GPs’ and specialists’ patients were 2.87
±1.00 mmol/l and 2.77 ±1.10 mmol/l, respectively
(Table I). Figure 1 presents changes in LDL-C level
between 2004 and 2011; it shows a decrease of
almost 1.0 mmol/l for patients treated by GPs. 
In Figure 2 the rate of GPs’ patients achieving the
2.50 mmol/l LDL-C target value is presented; this
was 40% in 2011, while that of specialists’ patients
proved to be 45% (p = 0.137). The change in goal
achievement rate of GPs between 2010 and 2011
proved to be statistically significant (p = 0.035),
while that of specialists (39% in 2010 [18] and 45%
in 2011) was not significant (p = 0.064). 
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Among specialists the plan of the physician
regarding the treatment of patients whose LDL-cho-
lesterol level was not on goal was evaluated. In 68%
of the cases the physician did not go further, and
the patients were left undertreated. In 32% of the
patients with LDL level over 2.50 mmol/l the fol-
lowing plans were declared for the change of cur-
rent treatment: in 34% doubling the dose of statin,
in 43% switching to a stronger statin and in 21%
introduction of combination therapy (in 2% of cas-
es the plan for therapy modification was not prop-
erly declared). 
Figure 3 shows the distribution of LDL-C values
in the GPs’ patients of the MULTI GAP 2011 study.
The achievement rate of 2.50 mmol/l LDL-C was
40%, but that of 1.80 mmol/l was only 11%. 
The 2011 MULTI GAP study also evaluated the
patients’ compliance with the lipid-lowering med-
ical treatment. This was estimated by the physician
based on questioning the patient and the frequency
of drug prescriptions. The result was given in per-
centage. Five groups were formed based on com-
pliance: 60% or below, 61-70%, 71-80%, 81-90% and
over 90% of patients were considered cooperative
in each group, respectively. The 2.50 mmol/l LDL-C
target achievement rate was 20%, 25%, 28%, 36%
and 42%, respectively (Figure 4).
Physician Patient Total LDL HDL Triglyceride
number cholesterol cholesterol cholesterol [mmol/l]
(n) [mmol/l] [mmol/l] [mmol/l] Mean ± SD
Mean ± SD Mean ± SD) Mean ± SD
GPs 474 5.12 ±1.30 2.87 ±1.01 1.26 ±0.34 1.99 ±1.67
Specialists 1152 4.97 ±1.25 2.77 ±1.10 1.29 ±0.43 2.05 ±1.23
Gender 943 males/683 females
Age [years] 66 ±10
BMI (body mass index) 29.0 ±10 kg/m2
Waist circumference: Males > 102 cm 39%
Females   > 88 cm 71%
eGFR 61 ±13 ml/min/1.73 m2
Smokers 27%
Unstable angina 383 (23%)
Previous myocardial infarction 560 (34%)
Known peripheral artery disease:
• (PAD) or vascular operation due to PAD 283 (17%)
• Transitory ischemic attack 279 (17%)
• Diabetes 766 (46%)
• Hypertension 1430 (88%)
Lipid lowering therapy (statin, patients’ %,/mean daily dose)
• Simvastatin 18%/29 mg
• Atorvastatin 46%/32 mg
• Rosuvastatin 29%/20 mg
• Fluvastatin 3%/72 mg
• Ezetimibe 16%/10 mg
• Fibrates 7%/201 mg
Table I. Characteristics and mean lipid values of the patients of GPs and specialists in the Hungarian MULTI GAP
2011 study
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Figure 1. Change in mean LDL-cholesterol levels of
high cardiovascular risk patients treated by GPs and
specialists, over the years
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Discussion
The clinical benefit of lipid-lowering therapy is
indisputable and has increasing importance in car-
diovascular prevention. According to the new dys-
lipidemia guidelines of the ESC/EAS 1.80 mmol/l
LDL-cholesterol is recommended for more patients
than before [10]. This means that more effort
should be made, since even the achievement rate
of the 2.50 mmol/l level could not meet our satis-
faction. The medication possibilities are limited
(statins and ezetimibe) and in the next few years
introduction of a new ground-breaking LDL choles-
terol-lowering agent is not expected. Also a few
more years must elapse until the promising PCSK9
inhibitor therapy [20] comes into practice. The
improvement of lipid parameters beyond LDL-C can
happen more frequently with the administration of
niacin and fibrates. Also the introduction of CETP
inhibitors may occur. These may decrease LDL-C lev-
els as well, but substantial improvement can be
expected only from a more effective use of the
statin + ezetimibe combination [21]. 
We have been analyzing the changes in lipid lev-
els and the achievement of the targets in Hungary
since 2004 [17, 18]. After the significant fall of lipid
levels experienced in the early years, recently stag-
nation has been observed. We could not be satis-
fied with attainment of the 2.50 mmol/l LDL-C lev-
el either, and regarding the significantly increased
and probably further increasing demands to reach
the level of 1.80 mmol/l, we have to look for addi-
tional ways to improve. 
The Hungarian CORVUS (COntrolled TaRgets for
High Vascular Risk Patients Using Effective Statins)
study investigated the effect of switching to rosu-
vastatin on the success of lipid lowering therapy in
1385 high risk patients. In this 3-month, multicen-
ter, prospective, observational, non-interventional,
open-label study during the treatment period the
level of total cholesterol decreased by 25.2% and
LDL cholesterol by 35.0%; at the end of the study
the rate of achieving the 2.50 mmol/l LDL-C target
level was 58%. One thousand and seventy-seven
out of 1385 patients belonged to the very high risk
category, and in this group of patients the 1.80
mmol/L LDL-C achievement rate proved to be only
19% [22, 23]. This result suggests that statin
monotherapy, even in the case of the most potent
rosuvastatin, in the majority of very high risk
patients is ineffective and the administration of eze-
timibe is inevitable.  
In the MULTI GAP 2010 study, comparing statin
monotherapy vs. combination therapy, a 19% dif-
ference was shown in the 2.50 mmol/l LDL-choles-
terol achievement rate in favour of the latter, i.e.
ezetimibe administration [18].
A further tool of achieving better lipid lowering
results could be the improvement of therapeutic
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Figure 2. Changes in the ratio of patients reaching
the target 2.50 mmol/l of LDL-cholesterol level treat-
ed by GPs between 2004 and 2011
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Figure 3. The distribution of LDL-C values in the
patients of GPs in the MULTI GAP 2011 study
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Figure 4. The relationship between the attainment
of 2.50 mmol/l LDL-cholesterol level and the patients’
compliance in the MULTI GAP 2011 study
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cooperation of the patients. A series of studies has
proven a linear correlation between patients’ adher-
ence to lipid lowering therapy and long-term sur-
vival or rate of clinical events [24-26]. In our 2010
study there was a 17% difference in target level
attainment rate between the good and bad com-
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pliance group [18]. The MULTI GAP 2011 study
proved again the linear correlation between the
patients’ cooperation in drug taking and achieve-
ment of the LDL-C target value (Figure 4); there was
not a statistically significant difference compared
with the results of 2010.
The patients’ willingness to cooperate is crucial.
In a recent study, according to the database of the
Hungarian National Health Insurance Fund, the dis-
pensation rate of prescribed statins in patients’
newly placed on statin therapy was analyzed and
it showed that in the second and third months of
the treatment about half of the patients did not go
to the pharmacy for the prescribed drugs and a year
later this proportion became only 26.3% [27]. The
most obvious possibility for improvement is that at
every drug prescription the patient’s attention
should be drawn to the long-term commitment as
the treatment needs appropriate cooperation in
order to maximize the benefits and reduce the fre-
quency of clinical events.
In the MULTI GAP 2010 study the physicians
receiving special education and access to software
which called attention to the patients’ weaknesses
in achieving their lipid goals had 10-11% better
results in reaching the 2.5 mmol/l LDL-C target lev-
el than doctors without the special education [18].
This supports the ideas of further education and use
of computer software application which facilitates
their work while both enhance target achievement
rates. According to the MULTI GAP 2011 survey 68%
of the physicians do not modify the therapy when
the patients’ lipid results do not meet the targets.
This high number confirms the fact that the con-
tinuing education of physicians is essential. For this
Table II may serve as guidance showing which ther-
apeutic options (dose doubling, switching to
a stronger statin or combination with ezetimibe) to
choose depending on the appropriate target value
(2.50 mmol/lor 1.80 mmol/l) and the current LDL-C
level. Experience shows that physicians need and
are willing to receive help from such materials.
In conclusion, we can summarize that target lev-
el achievements indicating the quality of treatment
in lipid-lowering therapy have significantly improved
in recent years; however, the momentum of
improvement came to a halt. To achieve further
improvements possibilities are available both at the
patients’ and doctors’ sides. On one side, continu-
ous monitoring of patients’ co-operation is needed
to improve their adherence. The physician should
inform the patient that the lipid-lowering therapy
is a lifelong activity which, if successful, could stop
the process of atherosclerosis and regression can
be achieved. On the other side, at every doctor-
patient meeting the importance of management
should be emphasized and after each laboratory
control the previous treatment should be reviewed.
This belongs to the improvement of medical activ-
ity. The key to improving the quality of lipid-lower-
ing is based on the doctor’s knowledge and his/her
attitude to the lipid-lowering therapy and these can
be assisted by MULTI GAP or other similar surveys.
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